Company intelligence / Profile preview

Athenagen

South San Francisco, California, United Statesathenagen.com ↗

Ownership: Private
Development stage: Other

Overview

Athenagen's lead candidate, GTS-21 (an alpha-7 nACh receptor agonist), reached Phase II for Alzheimer's disease with supportive preclinical and clinical data in cognition. ATG003, a topical anti-angiogenesis agent for AMD, entered Phase I, and beta-secretase inhibitors for Alzheimer's approached clinical entry before its transition to CoMentis.

Therapeutic areas: OphthalmologyEndocrinologyNeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Athenagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Athenagen.

Explore the full profile